At a recent meeting of the AAMI Healthcare Technology Safety Institute, researchers from the University of Toronto released a report that provides nine specific recommendations to reduce the risks ...

Evaluation of race as a prognostic factor in multiple myeloma. An ancillary of Southwest Oncology Group Study 8229. Patients with advanced malignancies were eligible. There were two treatment cycles; ...

Leipzig and Berlin, Germany - In the setting of acute ST-elevation MI (STEMI) treated with PCI, giving the initial bolus of abciximab (ReoPro, Eli Lilly/Centocor) by the intracoronary (IC) route, ...

Objective: To reanalyze data from two previous studies to provide stronger evidence of benefit for early use of single-dose intravenous bolus salbutamol in children with acute severe exacerbations of ...

Interim safety summary of alemtuzumab vs. chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL) This is an ASCO Meeting Abstract from the 2004 ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Use of a single IV bolus of cyclosporine ...

Patients over 16 years with suspected sepsis should get smaller amounts of intravenous fluid initially and then have regular reassessments to tailor treatment, updated guidelines recommend.1 At least ...

The glycoprotein IIb/IIIa inhibitor abciximab given as an intracoronary rather than intravenous (IV) bolus in patients undergoing primary percutaneous coronary intervention (PCI) may improve ...

The VE response to I.V. bolus infusion of Dox is largely unkown, although Dox is used parenterally in the treatment of apnea of infancy. The objectives of this study were 1) to determine if VE ...

LIDOCAINE (Xylocaine) has become one of the most frequently used drugs in the treatment of ventricular arrhythmias, particularly those associated with acute myocardial infarction. It has been shown to ...

In the UK, four thrombolytic agents are licensed and available to treat AMI. All act by promoting the activity of circulating plasminogen. There is a long history of use of one, streptokinase, whereas ...